Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel purification and renaturation method and antitumor application of recombinant endostatin

A column purification and vascular endothelium technology, which is applied in the fields of genetic engineering and biomedicine, can solve the problems of low soluble protein yield, low yield, and limited clinical promotion and use of protein drugs.

Active Publication Date: 2016-01-06
苏州方舟医药研发有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The recombinant human vascular endothelial cell somatostatin (rhEndostatin, rhED) currently in the clinical trial phase is mostly derived from the eukaryotic yeast expression system, which has high cost and low yield, which greatly limits the clinical application of this protein drug.
[0004] The endostatin produced by the prokaryotic expression system is difficult to refold and the yield of soluble protein is extremely low. Most of the research experiments are carried out by direct injection of inclusion bodies, which limits the effectiveness of its therapeutic effect.
[0005] In view of the difficulties in prokaryotic expression and yeast expression of recombinant human endostatin in the above-mentioned prior art, a recombinant human endostatin that is currently on the market in China has a very short half-life of only 2 hours, which greatly limits its anticancer activity. to play

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel purification and renaturation method and antitumor application of recombinant endostatin
  • Novel purification and renaturation method and antitumor application of recombinant endostatin
  • Novel purification and renaturation method and antitumor application of recombinant endostatin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0081] Embodiment 1, obtaining rhED inclusion body

[0082] The amino acid sequence of the designed recombinant rhED is shown in SEQ ID NO:2; its cDNA is shown in SEQ ID NO:1. Compared with the natural sequence, the ATG of this recombinant rhED is followed by "AGAGGATCC" encoding arginine, glycine and serine. "CACCATCATCATCATCAC" encoding 6×His was added upstream of the 3' TGA of the sequence.

[0083] Construction of pQE3 expression vector with rhED cDNA: the above rhED cDNA was obtained by gene synthesis, and inserted into the BamHI and HindIII sites of pQE3 (QIAGENUSA).

[0084] The pQE3 expression vector carrying rhED cDNA was transfected into Escherichia coli (E.ColiM15) to obtain rhED-producing bacteria, and the expression was induced with IPTG (0.25G / L), cultured at 37°C for 4 hours, and the bacteria were harvested by centrifugation at low temperature for 30 minutes and lysed. The recombinant rhED inclusion body was dissolved in 6M guanidine hydrochloride solution (0....

Embodiment 2

[0085] Example 2, optimization of purification and renaturation scheme of rhED

[0086] Scheme 1, scheme A of urea gradient solution dialysis-purification

[0087] The renaturation step of dialysis with urea gradient solution: diluent (0.05mol / Ltris, 2mmol / LEDTA, 3.5mol / L urea, 4mmol / L reduced glutathione (GSH), 0.4mmol / L oxidized glutathione Glycine (GSSG, pH8.0) dilute the inclusion body solution dissolved in guanidine hydrochloride to 0.3 mg / mL, dialyze with the dialysate A-G in Table 1 in sequence at 4°C, dialyze each dialysate once, each time for 24 hours, The ratio of the inner and outer fluids of the dialysis bag was 3:20, the inner fluid was 3.5M urea sodium acetate buffer, and the composition of the outer fluid (dialysis fluid) was shown in Table 1.

[0088] Table 1

[0089]

[0090] After refolding, centrifuge at 10000rpm for 15min, discard the precipitate, and the supernatant is the refolded rhED protein. Take OD 595 Draw a standard curve corresponding to the...

Embodiment 3

[0109] Example 3, rhED inhibits HUVEC cell growth and chicken embryo allantoic membrane angiogenesis inhibition

[0110] 1. rhED inhibits the growth of human umbilical vein endothelial cells (HUVEC)

[0111] Human umbilical vein endothelial cells (HUVEC) were purchased from ATCC and cultured in M199 basal medium containing 10% heat-inactivated fetal bovine serum and double antibodies. In the growth inhibition experiment, HUVEC was divided into 5×10 3 Each hole was inoculated on a 96-well plate with a volume of 100 μl, and cultured for 72 hours with the following culture solution (200 μl volume): (1), M199 basal culture solution+bFGF (5 ng / ml); (2), (1 )+0.1μg / mlrhED; (3), (1)+0.2μg / mlrhED; (4), (1)+0.5μg / mlrhED; (5), (1)+1μg / mlrhED; (6), ( 1) + 2 μg / mlrhED; (7), (1) + 5 μg / mlrhED; (8), (1) + 8 μg / mlrhED; (9), (1) + 16 μg / mlrhED. Then 20 μl MTT (5%) was added to each well, discarded after incubation for 4 hours, and shaken with 100 μl DMSO on a shaker for 15 minutes, and the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel purification and renaturation method and an antitumor application of recombinant endostatin, and discloses a renaturation and purification method of a novel recombinant human vascular endothelial cell growth inhibin inclusion body for the first time. A purified rhED protein can be obtained through the method in a low-cost and high-yield manner, and has excellent bioactivity and drug effects.

Description

technical field [0001] The invention relates to the fields of genetic engineering and biomedicine, more specifically, the invention relates to a novel purification and refolding method of recombinant endostatin and its anti-tumor application. Background technique [0002] Inhibiting angiogenesis has become a new target for clinical anti-tumor therapy. The occurrence, growth and metastasis of tumors depend on the blood vessels around the tumor to provide nutrients and pathways, and the maximum growth of tumors without normal blood supply does not exceed 1-2mm 2 . Cutting off the blood supply of tumor tissue may indirectly kill tumor cells and inhibit the metastasis of tumor cells, so as to achieve the purpose of treating tumors. More importantly, traditional cytotoxic chemotherapy drugs will cause serious cytotoxic effects due to dose accumulation, and the genetic heterogeneity of tumor cells themselves leads to drug resistance, which greatly limits the effect of such chemo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/475C07K1/22A61K38/18A61K33/24A61K31/675A61P35/00
Inventor 蒋永平蒋文宏任志华丁欣欣戴卫
Owner 苏州方舟医药研发有限公司